REGENXBIO INC. (NASDAQ:RGNX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

REGENXBIO INC. (NASDAQ:RGNX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Story continues below

On January26, 2018, the Company entered into the Separation Agreement with Mr.Ali in connection with his resignation as the Company’s Chief Business Officer. to the terms of the Separation Agreement, (i)Mr.Ali will receive a lump sum amount of $107,059, with respect to his 2017 cash incentive bonus, (ii)Mr.Ali will receive salary continuation payments in an aggregate amount of up to $238,359, to be paid on a bi-weekly basis for up to nine months following the effectiveness of the Separation Agreement and (iii)the Company will pay the premiums associated with Mr.Ali’s continuation health coverage for up to nine months following his resignation. The Company’s obligation to make the salary continuation payments to Mr.Ali described in (ii)above will cease on the date he commences employment with any other person or entity, and Mr.Ali’s eligibility to receive the healthcare benefits described in (iii)above will cease as of the date he is offered participation in substantially equivalent coverage in connection with any new or self-employment. The Settlement Agreement also contains a release by Mr.Ali of any claims against the Company arising from or relating to his employment and customary confidentiality, non-disparagement and cooperation covenants.

Mr.Ali may revoke the Separation Agreement for a period of seven days following its execution, after which time it will become effective. If Mr.Ali exercises his revocation right, the amounts referenced in (ii)and (iii) in the preceding paragraph will not be paid.

The foregoing summary of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the Separation Agreement, which is filed herewith as Exhibit 10.1 and incorporated herein by reference.

Item 5.02. Financial Statements and Exhibits.

(d) Exhibits


REGENXBIO Inc. Exhibit
EX-10.1 2 d507074dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (“Release”) is between Faraz Ali (“Employee”) and REGENXBIO Inc. (“REGENXBIO” or “Employer”),…
To view the full exhibit click here

About REGENXBIO INC. (NASDAQ:RGNX)

REGENXBIO Inc. is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors). Its NAV Technology Platform is applied in the development of approximately 30 product candidates for a range of diseases, including over five internally developed product candidates and approximately 20 partnered product candidates developed by its NAV Technology Licensees. Its therapeutic programs include RGX-501 for Homozygous familial hypercholesterolemia (HoFH); RGX-111 for Mucopolysaccharidosis Type I (MPS I); RGX-121 for Mucopolysaccharidosis Type II (MPS II); RGX-314 for Wet age related macular degeneration (wet AMD), and RGX-321 for X-linked retinitis pigmentosa (XLRP).

An ad to help with our costs